Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) saw a significant decline in short interest in August. As of August 31st, there was short interest totalling 536,500 shares, a decline of 19.5% from the August 15th total of 666,400 shares. Based on an average trading volume of 569,500 shares, the short-interest ratio is presently 0.9 […]
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings. Institutional & Insider Ownership 13.4% of Cardiff […]
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the target of a large decrease in short interest during the month of July. As of July 15th, there was short interest totalling 492,900 shares, a decrease of 8.2% from the June 30th total of 537,000 shares. Based on an average daily trading volume, of 149,600 […]
Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and Idorsia (OTCMKTS:IDRSF – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings. Analyst Recommendations This is a breakdown of current recommendations […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective lowered by HC Wainwright from $15.00 to $14.00 in a research report sent to investors on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Cardiff Oncology’s Q2 2023 earnings at ($0.26) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 earnings at […]